Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
84
ONWRF Quote, Financials, Valuation and Earnings
Last price:
$5.35
Seasonality move
:
42.68%
Day range:
$5.35 - $5.35
52-week range:
$4.41 - $7.04
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
196.73x
P/B ratio:
4.11x
Volume:
--
Avg. volume:
332
1-year change:
-10.08%
Market cap:
$299.6M
Revenue:
$83.3K
EPS (TTM):
-$0.81
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ONWRF
Onward Medical NV
|
-- | -- | -- | -- | -- |
|
ARGX
argenx SE
|
$1.4B | $6.87 | 87.13% | 205.62% | $1,010.28 |
|
MRUS
Merus NV
|
$10.9M | -$1.29 | -7.07% | -135.86% | $97.00 |
|
PHAR
Pharming Group NV
|
$92.7M | $0.03 | 11.23% | -90.74% | $31.00 |
|
PRQR
ProQR Therapeutics NV
|
$5.6M | -$0.17 | 32.53% | -55.96% | $8.88 |
|
QURE
uniQure NV
|
$6.9M | -$0.90 | 8.51% | -38.17% | $55.30 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ONWRF
Onward Medical NV
|
$5.35 | -- | $299.6M | -- | $0.00 | 0% | 196.73x |
|
ARGX
argenx SE
|
$844.92 | $1,010.28 | $52B | 42.95x | $0.00 | 0% | 18.02x |
|
MRUS
Merus NV
|
$96.92 | $97.00 | $7.4B | -- | $0.00 | 0% | 121.83x |
|
PHAR
Pharming Group NV
|
$17.80 | $31.00 | $1.2B | 1,244.76x | $0.00 | 0% | 3.35x |
|
PRQR
ProQR Therapeutics NV
|
$2.17 | $8.88 | $228.6M | -- | $0.00 | 0% | 13.13x |
|
QURE
uniQure NV
|
$24.81 | $55.30 | $1.5B | -- | $0.00 | 0% | 84.77x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ONWRF
Onward Medical NV
|
-- | 1.243 | -- | -- |
|
ARGX
argenx SE
|
-- | 0.059 | -- | 4.92x |
|
MRUS
Merus NV
|
1.57% | 2.127 | 0.17% | 7.55x |
|
PHAR
Pharming Group NV
|
33.1% | -0.371 | 13.18% | 2.39x |
|
PRQR
ProQR Therapeutics NV
|
20.36% | 3.523 | 7.64% | 3.23x |
|
QURE
uniQure NV
|
69.92% | 0.547 | 14.65% | 6.94x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ONWRF
Onward Medical NV
|
-- | -- | -- | -- | -- | -- |
|
ARGX
argenx SE
|
$837.2M | $203.8M | 24.23% | 28.06% | 30.38% | $312.8M |
|
MRUS
Merus NV
|
$11.5M | -$96.5M | -52.67% | -53.47% | -794.06% | -$90.4M |
|
PHAR
Pharming Group NV
|
$89.8M | $15.8M | 0.25% | 0.39% | 16.34% | $29.9M |
|
PRQR
ProQR Therapeutics NV
|
$2.6M | -$13.2M | -54.22% | -67.34% | -392.68% | -$15.4M |
|
QURE
uniQure NV
|
-$329K | -$50.7M | -40.98% | -382.35% | -1370.5% | -$17.7M |
Onward Medical NV vs. Competitors
-
Which has Higher Returns ONWRF or ARGX?
argenx SE has a net margin of -- compared to Onward Medical NV's net margin of 25.88%. Onward Medical NV's return on equity of -- beat argenx SE's return on equity of 28.06%.
Company Gross Margin Earnings Per Share Invested Capital ONWRFOnward Medical NV-- -- -- ARGXargenx SE88.32% $3.74 $6.1B -
What do Analysts Say About ONWRF or ARGX?
Onward Medical NV has a consensus price target of --, signalling downside risk potential of --. On the other hand argenx SE has an analysts' consensus of $1,010.28 which suggests that it could grow by 19.53%. Given that argenx SE has higher upside potential than Onward Medical NV, analysts believe argenx SE is more attractive than Onward Medical NV.
Company Buy Ratings Hold Ratings Sell Ratings ONWRFOnward Medical NV0 0 0 ARGXargenx SE15 2 0 -
Is ONWRF or ARGX More Risky?
Onward Medical NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison argenx SE has a beta of 0.366, suggesting its less volatile than the S&P 500 by 63.397%.
-
Which is a Better Dividend Stock ONWRF or ARGX?
Onward Medical NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. argenx SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Onward Medical NV pays -- of its earnings as a dividend. argenx SE pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ONWRF or ARGX?
Onward Medical NV quarterly revenues are --, which are smaller than argenx SE quarterly revenues of $948M. Onward Medical NV's net income of -- is lower than argenx SE's net income of $245.4M. Notably, Onward Medical NV's price-to-earnings ratio is -- while argenx SE's PE ratio is 42.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Onward Medical NV is 196.73x versus 18.02x for argenx SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ONWRFOnward Medical NV196.73x -- -- -- ARGXargenx SE18.02x 42.95x $948M $245.4M
-
Which has Higher Returns ONWRF or MRUS?
Merus NV has a net margin of -- compared to Onward Medical NV's net margin of -786.17%. Onward Medical NV's return on equity of -- beat Merus NV's return on equity of -53.47%.
Company Gross Margin Earnings Per Share Invested Capital ONWRFOnward Medical NV-- -- -- MRUSMerus NV94.71% -$1.26 $787.2M -
What do Analysts Say About ONWRF or MRUS?
Onward Medical NV has a consensus price target of --, signalling downside risk potential of --. On the other hand Merus NV has an analysts' consensus of $97.00 which suggests that it could grow by 0.08%. Given that Merus NV has higher upside potential than Onward Medical NV, analysts believe Merus NV is more attractive than Onward Medical NV.
Company Buy Ratings Hold Ratings Sell Ratings ONWRFOnward Medical NV0 0 0 MRUSMerus NV2 13 0 -
Is ONWRF or MRUS More Risky?
Onward Medical NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Merus NV has a beta of 1.061, suggesting its more volatile than the S&P 500 by 6.069%.
-
Which is a Better Dividend Stock ONWRF or MRUS?
Onward Medical NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merus NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Onward Medical NV pays -- of its earnings as a dividend. Merus NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ONWRF or MRUS?
Onward Medical NV quarterly revenues are --, which are smaller than Merus NV quarterly revenues of $12.2M. Onward Medical NV's net income of -- is lower than Merus NV's net income of -$95.5M. Notably, Onward Medical NV's price-to-earnings ratio is -- while Merus NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Onward Medical NV is 196.73x versus 121.83x for Merus NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ONWRFOnward Medical NV196.73x -- -- -- MRUSMerus NV121.83x -- $12.2M -$95.5M
-
Which has Higher Returns ONWRF or PHAR?
Pharming Group NV has a net margin of -- compared to Onward Medical NV's net margin of 7.71%. Onward Medical NV's return on equity of -- beat Pharming Group NV's return on equity of 0.39%.
Company Gross Margin Earnings Per Share Invested Capital ONWRFOnward Medical NV-- -- -- PHARPharming Group NV92.7% $0.11 $395.6M -
What do Analysts Say About ONWRF or PHAR?
Onward Medical NV has a consensus price target of --, signalling downside risk potential of --. On the other hand Pharming Group NV has an analysts' consensus of $31.00 which suggests that it could grow by 74.16%. Given that Pharming Group NV has higher upside potential than Onward Medical NV, analysts believe Pharming Group NV is more attractive than Onward Medical NV.
Company Buy Ratings Hold Ratings Sell Ratings ONWRFOnward Medical NV0 0 0 PHARPharming Group NV2 0 0 -
Is ONWRF or PHAR More Risky?
Onward Medical NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pharming Group NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ONWRF or PHAR?
Onward Medical NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharming Group NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Onward Medical NV pays -- of its earnings as a dividend. Pharming Group NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ONWRF or PHAR?
Onward Medical NV quarterly revenues are --, which are smaller than Pharming Group NV quarterly revenues of $96.9M. Onward Medical NV's net income of -- is lower than Pharming Group NV's net income of $7.5M. Notably, Onward Medical NV's price-to-earnings ratio is -- while Pharming Group NV's PE ratio is 1,244.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Onward Medical NV is 196.73x versus 3.35x for Pharming Group NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ONWRFOnward Medical NV196.73x -- -- -- PHARPharming Group NV3.35x 1,244.76x $96.9M $7.5M
-
Which has Higher Returns ONWRF or PRQR?
ProQR Therapeutics NV has a net margin of -- compared to Onward Medical NV's net margin of -381.88%. Onward Medical NV's return on equity of -- beat ProQR Therapeutics NV's return on equity of -67.34%.
Company Gross Margin Earnings Per Share Invested Capital ONWRFOnward Medical NV-- -- -- PRQRProQR Therapeutics NV76.72% -$0.12 $84.2M -
What do Analysts Say About ONWRF or PRQR?
Onward Medical NV has a consensus price target of --, signalling downside risk potential of --. On the other hand ProQR Therapeutics NV has an analysts' consensus of $8.88 which suggests that it could grow by 308.99%. Given that ProQR Therapeutics NV has higher upside potential than Onward Medical NV, analysts believe ProQR Therapeutics NV is more attractive than Onward Medical NV.
Company Buy Ratings Hold Ratings Sell Ratings ONWRFOnward Medical NV0 0 0 PRQRProQR Therapeutics NV7 0 0 -
Is ONWRF or PRQR More Risky?
Onward Medical NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ProQR Therapeutics NV has a beta of 0.176, suggesting its less volatile than the S&P 500 by 82.397%.
-
Which is a Better Dividend Stock ONWRF or PRQR?
Onward Medical NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProQR Therapeutics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Onward Medical NV pays -- of its earnings as a dividend. ProQR Therapeutics NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ONWRF or PRQR?
Onward Medical NV quarterly revenues are --, which are smaller than ProQR Therapeutics NV quarterly revenues of $3.4M. Onward Medical NV's net income of -- is lower than ProQR Therapeutics NV's net income of -$12.9M. Notably, Onward Medical NV's price-to-earnings ratio is -- while ProQR Therapeutics NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Onward Medical NV is 196.73x versus 13.13x for ProQR Therapeutics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ONWRFOnward Medical NV196.73x -- -- -- PRQRProQR Therapeutics NV13.13x -- $3.4M -$12.9M
-
Which has Higher Returns ONWRF or QURE?
uniQure NV has a net margin of -- compared to Onward Medical NV's net margin of -2175.87%. Onward Medical NV's return on equity of -- beat uniQure NV's return on equity of -382.35%.
Company Gross Margin Earnings Per Share Invested Capital ONWRFOnward Medical NV-- -- -- QUREuniQure NV-8.89% -$1.38 $760.4M -
What do Analysts Say About ONWRF or QURE?
Onward Medical NV has a consensus price target of --, signalling downside risk potential of --. On the other hand uniQure NV has an analysts' consensus of $55.30 which suggests that it could grow by 122.9%. Given that uniQure NV has higher upside potential than Onward Medical NV, analysts believe uniQure NV is more attractive than Onward Medical NV.
Company Buy Ratings Hold Ratings Sell Ratings ONWRFOnward Medical NV0 0 0 QUREuniQure NV9 2 0 -
Is ONWRF or QURE More Risky?
Onward Medical NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison uniQure NV has a beta of 0.586, suggesting its less volatile than the S&P 500 by 41.431%.
-
Which is a Better Dividend Stock ONWRF or QURE?
Onward Medical NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. uniQure NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Onward Medical NV pays -- of its earnings as a dividend. uniQure NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ONWRF or QURE?
Onward Medical NV quarterly revenues are --, which are smaller than uniQure NV quarterly revenues of $3.7M. Onward Medical NV's net income of -- is lower than uniQure NV's net income of -$80.5M. Notably, Onward Medical NV's price-to-earnings ratio is -- while uniQure NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Onward Medical NV is 196.73x versus 84.77x for uniQure NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ONWRFOnward Medical NV196.73x -- -- -- QUREuniQure NV84.77x -- $3.7M -$80.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
